It is likely that the transplantation of NSCs can provide not only a direct cell-replacing strategy for AD therapy, but also can be used as vehicles for the delivery of potential therapeutic agents, including neprilysin, insulin-degrading enzyme, plasmin and cathepsin B, to reverse AD pathologies [99, 100]. Here, CTSB is linked to Alzheimer disease.